Skip to content
Harbour BioMed
-
Harbour BioMed partner Solstice Oncology secures US$225M to target MSS colon cancer
Solstice Oncology plans to begin enrolment in a Phase II clinical trial of porustobart in combination with pembrolizumab in the fourth quarter of 2026.